Merck KGaA (MKKGY) Stock Price, News & Analysis

Company Overview

Merck KGaA, headquartered in Darmstadt, Germany, is a leading science and technology company with a heritage dating back to 1668. Over its more than three centuries of history, the company has evolved from a family-run apothecary into a global enterprise operating in the healthcare, life science and electronics sectors. Merck KGaA distinguishes itself by integrating chemistry, biotechnology and advanced materials to develop innovative solutions across a variety of industries.

In its Healthcare division, Merck KGaA focuses on prescription pharmaceuticals in areas such as oncology, immuno-oncology, neurology, fertility and endocrinology. The company’s portfolio includes targeted therapies, biologics and small-molecule drugs designed to address critical unmet medical needs. Through a robust pipeline and strategic collaborations, the division aims to advance novel treatments from early research to clinical application.

The Life Science arm serves academic research, biotech and pharmaceutical customers with an extensive range of products and services. These include lab reagents, cell culture media, instruments for analytical and preparative processes, and custom services for process development and manufacturing of biologics. By offering end-to-end solutions, Merck KGaA supports innovation throughout the drug discovery and production lifecycle.

Merck KGaA’s Electronics division supplies specialty materials for the semiconductor and display industries, including photoresists, high-purity chemicals and liquid crystals for flat-panel displays. With operations in over 60 countries, the company leverages its global footprint to meet regional market needs. Under the leadership of Chief Executive Officer Belén Garijo, Merck KGaA continues to invest in research and development, aiming to drive sustainable growth and address challenges in health, science and technology worldwide.

Key Stats

• Today's Range: $25.97 to $26.38
• 50-Day Range: $25.19 to $28.49
• 52-Week Range: $24.32 to $39.17
• Volume: 50,651 shs
• Average Volume: 175,999 shs
• Market Capitalization: $16.85 billion
• P/E Ratio: 12.35
• Dividend Yield: 1.30%
• Price Target: N/A
• Consensus Rating: Buy

Merck KGaA Stock Analysis - MarketRank™

Merck KGaA scored higher than 73% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Merck KGaA.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 9.63%

Earnings Growth

Earnings for Merck KGaA are expected to grow by 9.63% in the coming year, from $1.87 to $2.05 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Merck KGaA is 12.35, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.65.

Price to Earnings Ratio vs. Sector

The P/E ratio of Merck KGaA is 12.35, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.61.

Price to Earnings Growth Ratio

Merck KGaA has a PEG Ratio of 1.94. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Merck KGaA has a P/B Ratio of 0.52. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.01% of the float of Merck KGaA has been sold short.

Short Interest Ratio / Days to Cover

Merck KGaA has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Merck KGaA has recently decreased by 5.17%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Merck KGaA pays a meaningful dividend of 1.30%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Merck KGaA does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Merck KGaA is 16.11%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Merck KGaA will have a dividend payout ratio of 16.59% next year. This indicates that Merck KGaA will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.01% of the float of Merck KGaA has been sold short.

Short Interest Ratio / Days to Cover

Merck KGaA has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Merck KGaA has recently decreased by 5.17%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: N/A

News Sentiment

Merck KGaA has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.

MarketBeat Follows

1 people have added Merck KGaA to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Merck KGaA insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 0.10% of the stock of Merck KGaA is held by institutions.

MKKGY Stock Analysis - Frequently Asked Questions

How have MKKGY shares performed this year?

Merck KGaA's stock was trading at $28.63 at the beginning of the year. Since then, MKKGY stock has decreased by 8.9% and is now trading at $26.0750.

How were Merck KGaA's earnings last quarter?

Merck KGaA (OTCMKTS:MKKGY) announced its quarterly earnings results on Thursday, May, 15th. The company reported $0.59 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.50 by $0.09. The business earned $5.89 billion during the quarter, compared to analysts' expectations of $5.32 billion. Merck KGaA had a trailing twelve-month return on equity of 9.61% and a net margin of 13.23%.

How do I buy shares of Merck KGaA?

Shares of MKKGY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Ex-Dividend for 5/7 Dividend: 4/29/2025
• Record date for 5/7 Dividend: 4/30/2025
• Dividend Payable: 5/07/2025
• Last Earnings: 5/15/2025
• Today: 7/05/2025
• Next Earnings (Estimated): 8/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:MKKGY
• Previous Symbol: OTCMKTS:MKKGY
• CIK: N/A
• Web: www.merckgroup.com
• Phone: 496151720
• Fax: 49-61-5172-2000
• Employees: 62,557
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): $2.11
• Trailing P/E Ratio: 12.35
• Forward P/E Ratio: 13.94
• P/E Growth: 1.94
• Net Income: $3.00 billion
• Net Margins: 13.23%
• Pretax Margin: 16.86%
• Return on Equity: 9.61%
• Return on Assets: 5.59%

Debt

• Debt-to-Equity Ratio: 0.23
• Current Ratio: 1.31
• Quick Ratio: 0.83

Sales & Book Value

• Annual Sales: $22.57 billion
• Price / Sales: 0.75
• Cash Flow: $8.15 per share
• Price / Cash Flow: 3.20
• Book Value: $50.22 per share
• Price / Book: 0.52

Miscellaneous

• Outstanding Shares: 646,210,000
• Free Float: N/A
• Market Cap: $16.85 billion
• Optionable: Not Optionable
• Beta: 0.92